We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

Arguably the most exciting development for Gilead in 2025 will be the approval of lenacapavir, a long-acting (administered twice-yearly) therapy that has reported highly positive data from pivotal ...

traded higher in the premarket on Thursday after the antiviral developer posted interim data from a Phase 1 trial for ABI-4334, an investigational therapy it develops with Gilead (NASDAQ ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

In 2014, Gilead launched Harvoni, which combined two antiviral drugs ... The gene therapy companies have learned some lessons from Gilead Sciences. Value-based pricing can justify the hefty ...

She has also served as a consultant and advisor for Gilead. Assessment of antiviral therapy and monitoring in mothers at the phase of immune tolerance or inactive carrier. ALT, alanine ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...

When Galapagos and Gilead Sciences entered a global drug R&D collaboration ... is focusing on cell therapy, an area where Gilead already has a strong presence. Since the 2019 deal, both companies ...

Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of global commercial, he announced on LinkedIn this week. “CAR T-cell therapy has changed ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Emerging data suggest that antiviral therapy in the third trimester can ... Pan has received research grants from Gilead, Bristol Myers Squibb, Novartis, and Roche. He also serves as a consultant ...